AHEAD Study, the first trial that aims to help prevent Alzheimer’s, is recruiting participants as young as 55 at risk for dementia and using a new personalized medicine approach
Study launched during World Alzheimer’s Month
The first infusion of an investigational drug that aims to delay or help to prevent the earliest memory loss due to Alzheimer’s disease took place in September at Butler Hospital in Providence, R.I., researchers announced.
Funded by the National Institutes of Health (NIH) and Eisai Inc., a US subsidiary of Eisai Co., Ltd. (Headquarters: Tokyo), the AHEAD Study is the first Alzheimer’s disease trial to recruit people as young as 55 years old who are at risk of developing symptoms of Alzheimer’s disease as they get older. It introduces a personalized medicine approach that will tailor treatment dose levels to a participant’s particular risk of memory loss related to Alzheimer’s disease.
“We know that changes in the brains of people with Alzheimer’s disease begin up to 20 years before a person notices symptoms, but until now most clinical trials have included older patients who already have symptoms,” said Reisa Sperling, MD, director of the Center for Alzheimer’s Research and Treatment at Brigham and Women’s Hospital, Harvard Medical School and co-principal investigator for the AHEAD Study. “By inviting younger participants, we hope to help individuals who are at higher risk—such as people with family history—get ahead of the disease with early intervention. We also want to reach diverse communities to learn more about why people of color may be at higher risk of cognitive decline.”
The AHEAD Study consists of two different clinical trials testing the same investigational drug (known as BAN2401). Participants are enrolled in one of the two trials based on the level of amyloid in their brain. Amyloid is a protein that builds up in people who can go on to have memory problems and develop Alzheimer’s disease. The trial is led by experts at the University of Southern California’s Alzheimer’s Therapeutic Research Institute, the Alzheimer’s Clinical Trials Consortium, Brigham and Women’s Hospital, Massachusetts General Hospital, and Harvard Medical School.
“The personalized approach for people years before memory loss has begun has the potential to be a breakthrough in Alzheimer’s prevention,” said Stephen Salloway, MD, MS, and director of the Memory and Aging Program at Butler Hospital. “This new tailored approach can potentially serve as a model to improve clinical trials in Alzheimer’s research and other diseases.”
The sixth leading cause of death in the United States, Alzheimer’s is the only disease among the top 10 causes of death that cannot be prevented, cured, or slowed. Currently, 5.6 million Americans 65 and older are living with Alzheimer’s and this number is expected to nearly triple by 2050. Communities of color experience higher incidence of the disease than White communities, yet they remain underrepresented in clinical research.
“Both of my parents were diagnosed with Alzheimer’s disease. I can’t run away from that, but I can help find a potential treatment,” said Dave Kalberer, recipient of the first AHEAD infusion at Butler Hospital. “I’m proud to be at the front of the line for this exciting opportunity and am hopeful this trial can change not just my life but millions more.”
The AHEAD Study seeks 1,165 participants from North America. The study has more than 100 study locations worldwide, including North America, Japan, Singapore, Australia, and Europe.
Those in the Rhode Island area who are interested in participating in the AHEAD study are encouraged to join the Butler Hospital Alzheimer’s Prevention Registry online at butler.org/ALZregistry. The registry is used to screen interested individuals to see if they are likely to qualify for this and other studies being conducted at the Memory and Aging Program at Butler Hospital focused on Alzheimer’s prevention or treatment. Interested individuals may also call the program at (401) 455-6402 or e-mail email@example.com.
Passion for Fitness Fuels Sam Slezak’s Leadership in National Study to Protect Brain Health
Sam Slezak originally set out to become a trainer for professional athletes. Here’s how and why he became a project manager for a landmark national Alzheimer’s study instead.
Dr. Hwamee Oh Awarded NIH Grant for Study of Neuroimaging Markers of Early Alzheimer’s
The study seeks to identify new cognitive and neural biomarkers of preclinical Alzheimer’s disease, which would aid in earlier diagnosis and interventional treatment for the disease.
Katie Brandt Shares 5 Critical Dementia Caregiving Tips
Caregiver to both her young husband and her father with dementia, now she’s supporting others in the caregiver journey.
Butler Hospital among first in U.S. to launch new study of promising Alzheimer’s treatment
AHEAD 3-45 is a clinical trial for a treatment aimed at preventing cognitive decline in people with preclinical Alzheimer’s Disease (AD).
The Fight Against Alzheimer’s Continues Amid Coronavirus
MAP Director Dr. Stephen Salloway, along with other international leaders in the fight against Alzheimer’s, talk with the Providence Journal and WJAR NBC10 about how the fight to end Alzheimer’s continues despite coronavirus.
Drug studied at Butler Hospital could become first to meaningfully change course of Alzheimer’s
Aducanumab, an investigational drug for the treatment for Alzheimer’s disease, has been submitted to the FDA for approval with a request for Priority Review. If approved, it would become the first therapy to reduce the clinical decline of Alzheimer’s disease.
RI Chosen as 1 of 5 Sites for First Nationwide Study of Lifestyle Intervention to Reduce Risk of Cognitive Decline
The U.S. Study to Protect Brain Health Through Lifestyle Intervention to Reduce Risk (U.S. POINTER) is sponsored by the Alzheimer’s Association and is the first such study to be conducted in a large, diverse group of Americans across the United States.
Can smartphone technology detect preclinical Alzheimer’s? New study aims to find out.
Louisa Thompson, Ph.D., research scientist at Brown University and Butler Hospital, will evaluate how app-based and online cognitive tests might be used to detect subtle changes in memory and thinking associated with Alzheimer’s.
FDA Approves First Drug to Be Used as Tool for Diagnosing Alzheimer’s
Butler Hospital was one of 27 sites across the U.S. to study the drug flortaucipir through a partnership between its Memory and Aging Program and Rhode Island Hospital.